Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

Leukemia

Volumn 25, Issue 12, 2011, Pages 1910-1913

  Voso, M T ^a   Fabiani, E ^a   Piciocchi, A ^b   Matteucci, C ^c   Brandimarte, L ^c   Finelli, C ^d   Pogliani, E ^e   Angelucci, E ^f   Fioritoni, G ^g   Musto, P ^h   Greco, M ^a   Criscuolo, M ^a   Fianchi, L ^a   Vignetti, M ^b   Santini, V ⁱ   Hohaus, S ^a   Mecucci, C ^c   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b MDS   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f Ospedale Oncologico A Businco   (Italy)

^g Ospedale Civile Di Vicenza   (Italy)

^h REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; PROTEIN BCL 2; PROTEIN BCL2L10; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; EPIGENETICS; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LETTER; MISSENSE MUTATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; TET2 GENE; TREATMENT RESPONSE;

EID: 83555165094     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.170     Document Type: Letter

References (13)

1. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
2. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343-1345.
3. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
4. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
5. Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009; 15: 5002-5007.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. International Vidaza High-Risk MDS Survival Study Group.v Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
7. Fabiani E, Leone G, Giachelia M, D'alo F, Greco M, Criscuolo M et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-20-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010; 51: 2275-2284.
8. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Pic F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285-3291.
9. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMMLpatients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932.
10. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O et al. Impact of TET2 mutations on responserate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147-1152.
11. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009; 106: 16811-16816.
12. Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113: 4281-4288.
13. Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ et al. Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma. Histopathology 2010; 57: 814-824.